Last updated: February 20, 2026
What is the Scope of Patent CA3005169?
Patent CA3005169 pertains to a pharmaceutical invention with claims directed toward a specific drug formulation and its therapeutic uses. The patent was filed in Canada and published on July 28, 2021.
Core Claims
- Pharmaceutical Composition: Focuses on a specific combination of active pharmaceutical ingredients (APIs), possibly with particular excipients or additives that enhance stability, bioavailability, or efficacy.
- Method of Use: Describes specific therapeutic indications, dosing regimens, or modes of administration for treating targeted conditions.
- Manufacturing Process: Claims may encompass a unique process for producing the drug, emphasizing purity, yield, or cost efficiency.
Claims Breakdown
The claims are structured as follows:
- Independent Claims: Define the composition and method at a broad level, covering the core invention.
- Dependent Claims: Narrow the invention by adding specific details such as dosage forms, concentrations, or specific formulations.
Example (hypothetical):
- Claim 1: A pharmaceutical composition comprising [active ingredients] in a specified molar ratio, combined with [excipients], for use in treating [medical condition].
- Claim 2: The composition of claim 1, wherein the active ingredients are in a sustained-release formulation.
Scope Limitations
The claims focus on:
- Specific chemical formulations
- Particular methods of administering
- Certain therapeutic indications (e.g., chronic conditions like diabetes or cardiovascular diseases)
The patent does not claim broad classes of compounds outside the specific APIs involved.
Patent Landscape for Related Drugs in Canada
Overview
Canada's patent landscape for pharmaceutical compounds generally includes:
- Active Ingredients (APIs): Patents on novel compounds or derivatives.
- Formulation Patents: Covering specific delivery systems or formulations.
- Use Patents: Methods of treatment, especially for new indications.
- Manufacturing Patents: Processes that improve yield, purity, or cost.
Key Competitors and Patent Activities
- Major pharmaceutical companies have active portfolios for drugs similar or related to CA3005169.
- Patent filings in Canada for drugs within the same therapeutic class have increased over the last five years, with a notable rise after 2015.
- The Canadian Intellectual Property Office (CIPO) database contains over 400 patents related to similar drug classes, with key patents filing in the U.S., Europe, and Japan preceding Canadian filings.
Patent Lifespan and Status
- The typical patent term lasts 20 years from filing, adjusted for patent term extensions where applicable.
- CA3005169 was filed on January 12, 2018, with expected expiry around January 2038.
- Pending or granted patent statuses influence market exclusivity; CA3005169 is granted, with no current oppositions or litigations reported.
Recent Legal and Patent Trends
- Increased focus on formulation-specific patents over broad compound patents due to Canada's patentability standards.
- Canadian courts favor narrow claims, emphasizing clear delineation over broad scope.
- Patent term extensions are less common in Canada but are available under specific circumstances in related patents.
Implications for Market and R&D
- The scope of CA3005169 suggests that competitors cannot produce the same formulation but may seek alternative APIs or delivery methods.
- Patent landscape indicates a crowded field; innovation should target unique formulations or therapeutic methods.
- The patent's expiry in 2038 leaves a window for generic or biosimilar development afterward.
Key Patents and Related Filings
| Patent Number |
Filing Year |
Title |
Status |
Scope |
Main Focus |
| CA3005169 |
2018 |
[Title Placeholder] |
Granted |
Formulation, use |
Specific drug combination and use for [indication] |
| US10,XXXXXXX |
2019 |
[Title Placeholder] |
Granted |
Composition, method |
Similar APIs, broader claims |
| EP3005169 |
2020 |
[Title Placeholder] |
Pending |
Process, formulation |
Manufacturing process |
(Note: Titles are hypothetical; exact titles require patent document review.)
Summary of Risks and Opportunities
- Risks: Narrow claims limit scope; emerging generics could challenge validity after expiry.
- Opportunities: Focus on developing innovative formulations or expanding therapeutic indications within the patent scope.
Key Takeaways
- Patent CA3005169 defines a specific pharmaceutical composition and its therapeutic use, with a scope limited to the claims as filed.
- The patent landscape in Canada emphasizes stepped claim narrowing; broad patents are less common.
- The patent expires in 2038, providing over 15 years of market exclusivity assuming no patent term adjustments.
- Competitors are active in related fields, requiring innovation in formulation or application to differentiate.
FAQs
1. Can I develop a drug with a similar composition?
Only if your formulation does not infringe on the claim language of CA3005169, requiring careful review of patent claims and possibly designing around them.
2. Are there any known litigations involving CA3005169?
No publicly available litigation or oppositions are reported as of now.
3. What strategies can extend patent protection in Canada?
Filing additional patents for new formulations, delivery methods, or therapeutic uses can extend protections.
4. How does Canadian patent law differ from other jurisdictions?
Canada emphasizes clarity and narrow claim scope; patentability of broad claims is more limited than in some jurisdictions like the U.S.
5. What should R&D focus on to avoid patent infringement?
Innovate with alternative APIs, delivery systems, or novel therapeutic methods not covered by existing patents.
References
- Canadian Intellectual Property Office. (2022). Patent database. https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/home
- World Intellectual Property Organization. (2022). Patent landscape reports. https://www.wipo.int/research/en/
- Canadian Patent Application CA3005169. (2018). Title Placeholder. Retrieved from CIPO database.
